Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above 200 Day Moving Average – Here’s Why

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.58 and traded as high as $4.00. Sonoma Pharmaceuticals shares last traded at $3.86, with a volume of 14,047 shares trading hands.

Analyst Ratings Changes

Several analysts have commented on SNOA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sonoma Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Sonoma Pharmaceuticals to a “hold” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Trading Up 4.9%

The stock has a market capitalization of $6.34 million, a price-to-earnings ratio of -1.57 and a beta of 1.46. The stock’s 50 day moving average is $4.32 and its two-hundred day moving average is $3.58.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.14. The firm had revenue of $4.01 million during the quarter, compared to analyst estimates of $4.26 million. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. On average, research analysts anticipate that Sonoma Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management purchased a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.